Study of serum level of S100B as a biomarker of vitiligo activity

Abstract

BackgroundVitiligo is a common acquired depigmenting skin disorder. Current pathophysiologic insights promote the theory that melanocytes are destroyed by the immune system, leaving persistent areas of depigmentation, other theories have been suggested regarding the causes for depigmentation, including deficient adhesion proteins, an increased presence of oxidative stress, and neurogenic factors.ObjectiveThe study aims to evaluate the serum level of S100B in vitiligo patients and its correlation with disease activity in comparison with healthy controls.Patients and methodsThis is a case–control study that included 60 patients with vitiligo who were diagnosed with clinical evaluation and 30 healthy individuals as a control group. All patients were assessed for activity by Vitiligo Disease Activity Score (VIDA score) last year and the authors used Vitiligo Extent Score (VES), which is estimated body mass index % and measured serum level of S100B by the enzyme-linked immunosorbent assay system.ResultsThere was a significant increase in the serum level of S100Bng/l in the patient group compared with the control (P value < 0.001) and a significant positive correlation between serum level of S100Bng/l and VIDA in the patient group.ConclusionSerum levels of S100B in vitiligo were used as a biomarker for activity.